{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:58:45Z","timestamp":1787698725610,"version":"build-2784847793"},"reference-count":18,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,2,21]]},"abstract":"<jats:p>Levetiracetam is widely regarded as a benign antiepileptic drug, compared to older antiepileptic medication. We report a case of eosinophilic pneumonia due to levetiracetam use in a non-smoking woman aged 59\u2005years with no previous respiratory history. Our patient presented with exertional breathlessness and marked desaturation on exertion. She displayed \u2018reverse bat-wing\u2019 infiltrates on her chest radiograph and peripheral eosinophilia on a complete blood count. Her symptoms, radiology and peripheral eosinophilia resolved completely with cessation of levetiracetam and a course of prednisolone. This is the first report of isolated eosinophilic pneumonia due to levetiracetam. Other reports of levetiracetam-induced eosinophilia describe drug rash, eosinophilia and systemic symptoms (DRESS syndrome). Detection of pulmonary drug reactions requires a careful drug history and high index of suspicion. Identifying and reporting a causative agent is crucially important, as cessation of the drug is essential for resolution of the syndrome.<\/jats:p>","DOI":"10.1136\/bcr-2016-219121","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T11:00:28Z","timestamp":1488970828000},"page":"bcr2016219121","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Levetiracetam-induced eosinophilic pneumonia"],"prefix":"10.1136","volume":"2017","author":[{"given":"Aisling","family":"Fagan","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fuld","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Soon","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.2","unstructured":"Epilepsies: diagnosis and management. Nice.org.uk. 2012. (cited 29 January 2017). https:\/\/www.nice.org.uk\/guidance\/cg137\/chapter\/About-this-guideline"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","article-title":"Antiepileptic drugs and adverse skin reactions: an update","volume":"67","author":"B\u0142aszczyk","year":"2015","journal-title":"Pharmacol Rep"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clineuro.2012.01.019","article-title":"Antiepileptic drug-induced skin reactions: a retrospective study and analysis in 3793 Chinese patients with epilepsy","volume":"114","author":"Wang","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.43.s.3.5.x"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.6","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A032"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2008.03.032"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.8","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R084"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.9","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1002\/phar.1617","article-title":"Eosinophilia and fever with levetiracetam: a case report","volume":"35","author":"Flannery","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/0019-5154.177777","article-title":"Levetiracetam induced drug reaction with eosinophilia and systemic symptom syndrome","volume":"61","author":"Dar","year":"2016","journal-title":"Indian J Dermatol"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.11","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jemermed.2015.10.004","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome induced by levetiracetam in a pediatric patient","volume":"50","author":"Bayram","year":"2016","journal-title":"J Emerg Med"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.12","first-page":"31","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"6","author":"Choudhary","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.01.017"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.14","doi-asserted-by":"publisher","DOI":"10.2174\/138161206778193962"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.15","unstructured":"RegiSCAR. Regiscar.org. (cited 29 January 2017). http:\/\/www.regiscar.org\/Diseases_HSS_DRESS.html"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.16","doi-asserted-by":"publisher","DOI":"10.1159\/000069956"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.17","unstructured":"Camus P , Foucher P . Pneumotox \u2018Drug\u2019 [Internet]. Pneumotox.com. 1997. (cited 29 January 2017). http:\/\/www.pneumotox.com\/"},{"key":"2025082805262765000_2017.mar08_2.bcr2016219121.18","unstructured":"MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Fda.gov. (cited 29 January 2017). http:\/\/www.fda.gov\/Safety\/MedWatch\/default.htm"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-219121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:26:36Z","timestamp":1756383996000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-219121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":18,"alternative-id":["10.1136\/bcr-2016-219121"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-219121","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]}}}